Alina Riedinger-Berriolo

Dijon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Journal: Haematologica

Published: November 06, 2025

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: August 29, 2024

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.

Journal: The Lancet. Oncology

Published: March 14, 2024

High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.

High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.

Journal: Blood advances

Published: July 10, 2023

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.

Journal: Blood

Published: June 20, 2023

Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.

Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 14, 2023

Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.

Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.

Journal: Leukemia & lymphoma

Published: August 17, 2022

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2022

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.

Journal: Blood advances

Published: December 27, 2021

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.

Journal: Blood advances

Published: March 18, 2021

Effect of obesity, age and gender on glomerular filtration rate measured in normal adults

Effect of obesity, age and gender on glomerular filtration rate measured in normal adults

Journal: Annales de biologie clinique

Published: February 02, 2021

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.

Journal: Blood

Published: August 19, 2020

Showing 1-12 of 48

Last Updated: 09/26/2026